A Phase II Study of Clinical Outcomes of 3-Week Cycles of Irinotecan and S-1 in Patients with Previously Untreated Metastatic Colorectal Cancer: Influence of the UGT1A1 and CYP2A6 Polymorphisms on Clinical Activity

Publisher： Karger

E-ISSN： 1423-0232|82|5|290-297

ISSN： 0030-2414

Source： Oncology, Vol.82, Iss.5, 2012-04, pp. : 290-297

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase II Study of Irinotecan plus S-1 Combination for Previously Untreated Advanced Non-Small Cell Lung Cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0601

By  

Oncology, Vol. 81, Iss. 2, 2011-10 ,pp. : 84-90

Karger

Access to resources Recommend Favorite

A Phase I Study of UGT1A1 *28/*6 Genotype-Directed Dosing of Irinotecan (CPT-11) in Korean Patients with Metastatic Colorectal Cancer Receiving FOLFIRI

By  

Oncology, Vol. 88, Iss. 3, 2014-11 ,pp. : 164-172

Karger

Access to resources Recommend Favorite

A Phase II Study of Combined Chemotherapy with 5-Week Cycles of S-1 and CPT-11 plus Bevacizumab in Patients with Metastatic Colon Cancer

By  

Oncology, Vol. 85, Iss. 6, 2013-11 ,pp. : 317-322

Karger

Access to resources Recommend Favorite

Phase II Study of S-1 Combined with Irinotecan (CPT-11) in Patients with Advanced Colorectal Cancer

By  

Oncology, Vol. 77, Iss. 3-4, 2009-09 ,pp. : 192-196

Karger

Access to resources Recommend Favorite

A Phase II Trial of Combined Chemotherapy with Oral S-1 and 24-Hour Infusions of Irinotecan plus Bevacizumab in Patients with Metastatic Colorectal Cancer

By  

Oncology, Vol. 88, Iss. 6, 2015-0 ,pp. : 353-359

Karger

Access to resources Recommend Favorite